跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2019/11/022073
CTRI/2019/11/022073尚未招募未知

A Multicentric, Open Label, Balanced, Randomized, Two-Period, Two Sequence, Crossover, Steady State, Food Effect Study of Clozapine Extended Release Capsule 200 mg Once Daily (Test drug, Intas Pharmaceuticals Limited, India) After Multiple Dose Administration in Adult Schizophrenic Patients Under Fasting and Fed Condition.

Intas Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
尚未招募
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •1. Written informed consent for participation in the study by the patient and Patient Legally Acceptable Representative (LAR).
  • •2. Patient has a documented clinical diagnosis of schizophrenia according to DSM 5 at least six months prior to screening.
  • •3. Patients have a diagnosis of treatment-resistant schizophrenia (Treatment resistance is the failure to respond to two or more antipsychotic medications given in therapeutic dose for atleast six weeks).
  • •4. Male and female patients between 18 and 60 years of age (both inclusive).
  • •5. Non-smokers.
  • •6. Male patients with weight >= 50 kg and female patients with weight >= 45 kg.
  • •7. Not having any significant diseases or clinically significant abnormal findings except schizophrenia during screening-including medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (posteroanterior view) recording, ophthalmic examination etc. which is likely to
  • •adversely affect patient safety by participating in the study or study objectives
  • •in investigator opinion.
  • •8. The investigator must ensure that the respective hepatic, renal, haematopoietic,
  • •cardiac and respiratory functions are appropriate to include the patient in the
  • •9. Patients have been on a daily stable dose of 200 mg clozapine formulation for at least 3 month prior to screening visit.
  • •10. Able to comply with study procedures in the opinion of the investigator.
  • •11. In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
  • •12. Sexually active women, unless surgically sterile (at least 6 months prior to study
  • •drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.

排除标准

  • •1. Patient with known hypersensitivity/ intolerance to clozapine or any other component of the drug.
  • •2. Clinically symptomatic orthostatic hypotension.
  • •Note: Orthostatic hypotension is defined as a drop in systolic blood pressure of 20 mm Hg or more and/or a drop in diastolic blood pressure of 10 mm Hg or more on standing.
  • •3. Concurrent use of antihypertensive medication or any medication that might predispose to orthostatic hypotension.
  • •4. Supine blood pressure less than 110/70 mm Hg or pulse rate less than 60 or more than 100 beat per minute at screening and Day 0.
  • •5. Concurrent primary psychiatric or neurological diagnosis (except schizophrenia),
  • •including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinson disease.
  • •6. An absolute neutrophil count <1500/μL performed at the screening and a day prior to randomization.
  • •7. A history of granulocytopenia, agranulocytosis or myeloproliferative disorders
  • •(drug-induced or idiopathic).
  • •8. A history of epilepsy or risk for seizures, paralytic ileus, or multiple syncopal episodes.
  • •9. A medical or surgical condition that might interfere with the absorption, metabolism, or excretion of clozapine.
  • •10. Known case of poor metabolizer individuals with reduced activity of cytochrome P450 enzymes particularly, 1A2, 2D6 and 3A4.
  • •11. Ingestion of any restricted medication at any time within 07 days before the first
  • •study drug administration.
  • •12. Smokers, or who have smoked within last six months prior to start of the study.
  • •13. Positive tests for drug or alcohol abuse at screening and baseline.
  • •14. A history of alcohol or drug dependence by Diagnostic and Statistical Manual of
  • •Mental Disorders V (DSM 5) criteria during the 6-month period immediately
  • •prior to study entry.
  • •15. Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first
  • •dose of study medication or during the study.
  • •16. Receipt of an investigational medicinal product or participation in a drug research study within 90 days prior to receiving the first dose of study medication or during the study.
  • •17. A known case of or positive test for HIV infection or hepatitis B or HCV.
  • •18. Known history of hereditary problems of galactose intolerance, the Lapp lactase
  • •deficiency or glucose galactose malabsorption.
  • •19. Psychosis judged to be the direct physiological effect of an abused medication or
  • •20. Hospitalisation for an exacerbation of schizophrenia within two months prior to screening and during the screening period.
  • •21. Patients who, in the opinion of the investigator, pose an imminent risk of suicide
  • •or a danger to self or others.
  • •22. Patients with the following cardiac conditions are excluded:
  • •a. Recent myocardial infarction ( <12 months).
  • •b. QTc prolongation (screening electrocardiogram with QTc >450 msec).
  • •c. History of QTc prolongation or using concomitant medications which prolong QTc interval.
  • •d. First-degree heart block with PR interval > 0.22 seconds.
  • •e. Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia.
  • •f. Uncompensated congestive heart failure, myocarditis, cardiomyopathy.
  • •g. Complete left bundle branch block.
  • •23. Presence of narrow angle glaucoma assessed by tonometry.
  • •24. Patient w

研究者

相似试验

尚未招募
不适用
Comparative bioavailability study of Etoposide Capsules 100 mg in adult patients with platinum resistant or refractory ovarian cancer.
CTRI/2022/05/042819Intas Pharmaceuticals Ltd India
进行中（未招募）
1 期
Comparative pharmacokinetics study (study to know the amount of study drug (cyclophosphamide) in your blood at specified time points – to understand what body does to this study drug) of two products of cyclophosphamide powder for oral solution and Cyclophosphamide Tablets 50 mg in adult patients with breast cancerAdult female patients with breast cancer.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-004897-77-Outside-EU/EEAIntas Pharmaceuticals Ltd.
已完成
不适用
A study of cyclophosphamide powder for oral solution in adult patients with breast cancer.
CTRI/2021/11/037948Intas Pharmaceuticals LtdIndia
尚未招募
不适用
A study of Risperidone Long Acting Injection 25 Mg/ Vial In Patients Needing Treatment For Schizophrenia And/or Maintenance Therapy For Bipolar I Disorder
CTRI/2022/05/042538Intas Pharmaceuticals Ltd India
已完成
不适用
Bioequivalence study of asenapine sublingual tablets in patients
CTRI/2013/11/004152Amneal Pharmaceuticals LLC USA48